FDA clears narrow use of Lynparza in early prostate cancer — AstraZeneca drops Skyrizi rival after seeing R&D timeline spiral --FDA approves Pfizer’s RSV vaccine for older adults -- See more on our front page news http://bit.ly/w28kSd See more on our front page news
Dismiss Notice

Reply to Thread

Verification:: Answer the above question:

(CustomImgCaptcha By Surrey Forum)

Message:: [QUOTE="Anonymous, post: 3917527"]They had to make our quotas attainable for Q1 or else everyone would have left-yes happy to make money again (For Q1) but we don't have quotas for the year.  Management should be worried they look like assholes to J&J for last year's sales (Q1 was to save face and management jobs). Territory spilts will change compensation and threats of plan are not motivating.  Haven't had a new product in over a year-Sentry is not a new product. Working hard for a lot less pay over the long run.  J&J employees seem to like to jump from division to division and really seem lazy.  Give it 6 months and this will be the cakewalk you mentioned and this Company will be full of J&J has-beens from the other divisions who heard about the good old days (which they couldn't have hacked) and lured because of an ipad.[/QUOTE]